More answers like this
GPT-5Oct 11, 2026openai/gpt-5-2025-08-07
Should AI development be paused or restricted?
Short answer: A blanket pause on all AI is neither practical nor desirable. But targeted restrictions—and conditional pauses on the riskiest frontier systems—make sense.
A balanced approach
•Prohibit clearly dangerous uses now
•Autonomous weapons targeting people
•Real‑time mass surveillance and social scoring
•Models or tools explicitly optimized for bioweapon design, major cyber‑offense, or critical‑infrastructure sabotage
•High‑stakes decisions (credit, housing, employment, healthcare, justice) without meaningful human oversight and auditability
•Require conditional “pauses” when risk is high
•Before training or releasing models above defined capability/compute thresholds, mandate third‑party safety evaluations, red‑teaming, and documented mitigations. If developers can’t meet these requirements, they must delay.
•Trigger pauses when evaluations show dangerous emergent capabilities (e.g., autonomous replication, skilled cyber‑intrusion, or actionable bio‑design) until safeguards are proven effective.
•Guardrails that enable progress safely
•Licensing/registration for frontier training runs; basic disclosures about model scale, training data categories, and intended uses
•Independent pre‑deployment evaluations and post‑deployment monitoring, with incident reporting and recall powers for regulators
•Strong weight‑security and access controls for powerful models; staged release when dual‑use risk is high
•Data governance: consent and provenance where feasible, privacy protections, IP compliance, and opt‑out mechanisms
•Content provenance/watermarking and labeling for AI‑generated media to reduce fraud and misinformation
•Liability that is proportional to risk, plus mandatory risk insurance for high‑stakes deployments
•Open‑source nuance
•Encourage open models for low‑risk applications and research reproducibility.
•Use restricted or staged access (e.g., APIs, researcher licenses) for models with high misuse potential, paired with auditability and appeal processes to avoid entrenching incumbents.
•Enforcement and incentives
•Compute tracking and secure reporting for very large training runs
•Audits, fines, and injunctive powers for noncompliance; safe‑harbor protections for good‑faith disclosure of incidents
•Public funding for safety research, verification benchmarks, and evaluation infrastructure
Why not a blanket pause?
•It would likely push development to less regulated jurisdictions, entrench incumbents, and delay clear benefits (drug discovery, accessibility, education, climate modeling, safety tools) without reliably reducing global risk.
Bottom line
•Restrict specific harmful uses now.
•Impose conditional pauses for frontier training and release until independent evaluations and safeguards are in place.
•Keep low‑risk innovation moving with proportionate rules and transparency.
If you share your top concerns (misinformation, jobs, safety, national security, bias, etc.), I can tailor a concrete policy or company playbook.